Absolute monocyte count predicts overall survival in mantle cell lymphomas: Correlation with tumour-associated macrophages

Hematological Oncology

Volumn 32, Issue 4, 2014, Pages 178-186

  Koh, Young Wha ^a   Shin, Su Jin ^b   Park, Chansik ^b   Yoon, Dok Hyun ^b   Suh, Cheolwon ^b   Huh, Jooryung ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Macrophage; Mantle cell lymphoma; Mantle Cell Lymphoma International Prognostic Index (MIPI); Monocyte; Prognosis

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; EVENT FREE SURVIVAL; GRANULOCYTOSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTOSIS; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MONOCYTE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SOUTH KOREA; TUMOR ASSOCIATED LEUKOCYTE; AGED; BLOOD; CYTOLOGY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; LYMPHOMA, MANTLE-CELL; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; TREATMENT OUTCOME;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; ROC CURVE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84914099463     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2106     Document Type: Article

References (29)

1. Sant M, Allemani C, De Angelis R, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008; 44(4): 579-587.
2. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52(19 Suppl): 5432s-5440s.
3. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27(4): 511-518.
4. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16(5): 1922-1930.
5. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27(8): 1209-1213.
6. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111(2): 558-565.
7. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115(8): 1530-1533.
8. Shah JJ, Fayad L, Romaguera J. Mantle cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008; 112(6): 2583; author reply -4.
9. Mantovani A, Schioppa T, Porta C, et al. Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25(3): 315-322.
10. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8(8): 618-631.
11. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362(10): 875-885.
12. Wada N, Zaki MA, Hori Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60(2): 313-319.
13. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106(6): 2169-2174.
14. Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25(9): 1502-1509.
15. Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012; 53(4): 575-580.
16. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012; 97(2): 262-269.
17. Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012; 17(6): 871-880.
18. Krecsak L, Micsik T, Kiszler G, et al. Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer. Diagn Pathol 2011; 6: 6.
19. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer 2003; 89(2): 232-238.
20. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003; 74(1): 25-32.
21. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009a; 114(10): 2149-2158.
22. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109(12): 5276-5285.
23. Lau SK, Chu PG, Weiss LM. CD163 a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004; 122(5): 794-801.
24. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5(12): 953-964.
25. Seiffert M, Schulz A, Ohl S, et al. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 2010; 116(20): 4223-4230.
26. Wilcox RA, Wada DA, Ziesmer SC, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009b; 114(14): 2936-2944.
27. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64(3): 190-196.
28. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20(5): 1288-1294.
29. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23(9): 1984-1992.